PNLIP and obesity disorder: Among synthetic anti-obesity drugs, orlistat (tetrahydrolipstatin), an inhibitor of pancreatic lipase (EC 3.1.1.3), is the only currently approved weight loss medicine for the long-term treatment of obesity [61,62].